 |
|
|
| |
Evaluation of Pharmacokinetic Drug-Drug Interaction (DDI) Between BMS-791325, an NS5B Non-Nucleoside
Polymerase Inhibitor, Daclatasvir and Asunaprevir in Triple Combination in HCV Genotype 1-Infected Patients
|
| |
| |
Reported by Jules Levin
EASL Amsterdam April 25, 2013
Wang X, Li W, Huang S-P, He B, Chung E, Griffies A, Cooney E, Hughes EA, Kandoussi H, Sims K, Gardiner D, Bertz RJ, Eley T
Bristol-Myers Squibb, Princeton, NJ, USA
|
| |
|
|
|
|
|
